H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on AnaptysBio (ANAB) to $22 from $19 and keeps a Neutral rating on the ...

Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Viking Therapeutics in a research note issued on Thursday, February 6th. HC Wainwright analyst J. Pantginis expects that ...

H.C. Wainwright lowered the firm’s price target on Sage Therapeutics (SAGE) to $12 from $14 and keeps a Neutral rating on the shares. The ...

D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at ...

Cryptocurrency company Coinbase Global (NASDAQ:COIN) could highlight record profitability and user metrics when the company ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

H.C. Wainwright analyst Scott Buck revised the price target on Yatra Online (NASDAQ:YTRA) to $3.00 from the previous $4.00, while maintaining a Buy rating on the company's stock. The adjustment ...

H.C. Wainwright analyst Mike Colonnese increased the price target for Coinbase Global Inc. (NASDAQ:COIN) shares to $330, up from the previous $255, while maintaining a Buy rating on the stock. The ...

Proceeds expected to fund the start of the ALG-000184 Phase 2 clinical study Funding expected to extend cash runway into the second half of 2026 SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE ...

Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering ...